Warm Welcome | Shutong Technology Announces Mr. Wang Shuzhan Joins the Board, Continuously Advancing
Warm Welcome! | GeneRulor Technology Announces Mr. Wang Shuzhan Joins the Board, Continuously Advancing the Industrialization of Gene Editing
Recently, Zhuhai GeneRulor Medical Technology Co., Ltd. (hereinafter referred to as “GeneRulor”) announced that Mr. Wang Shuzhan, Managing Director of Yunfeng Capitalhas officially joined the company's board of directors as a representative of Yunfeng Capital.
This adjustment to the board of directors is an arrangement by GeneRulor to continuously improve corporate governance, advance technology platform construction, and foster industrial cooperation. In the future, Mr. Wang Shuzhan will leverage his experience in healthcare investment, life science industry insights, corporate strategic management, and resource coordination to support GeneRulor's long-term development and help enhance the company's comprehensive capabilities in gene editing technology research, development, and related service applications.
Lin Huabing, General Manager of GeneRulor, stated:
“We warmly welcome Mr. Wang Shuzhan to join the board of directors of GeneRulor. Currently, the gene editing and cell and gene therapy industries are in a phase of rapid development, with technological innovations continuously extending to clinical translation and industrial applications. At the same time, the industry has raised higher requirements for editing efficiency, safety evaluation, quality control, and regulatory submission support. Mr. Wang Shuzhan has extensive experience in healthcare industry investment, innovative enterprise growth, and strategic resource integration. We believe his joining will bring significant impetus to Shutong Technology's future development and further promote the company's continuous deepening of its layout in gene editing safety assessment and one-stop technology service platforms.”
Mr. Wang Shuzhan, Managing Director of Yunfeng Capital, stated:
“It is an honor to join the board of directors of GeneRulor. As the application of matchgene editing technology in the research and development of innovative therapies such as cell and gene therapy continues to deepen, the requirements of relevant R&D entities for clinical translation quality, risk identification, and data verifiability are also continuously increasing. For biopharmaceutical companies and research institutions advancing the development of innovative therapies, establishing a reliable technical service system encompassing editing tools, delivery systems, model construction, efficacy validation, safety evaluation, and regulatory submission support is of growing value. Shutong Technology has accumulated continuous expertise in related areas. I look forward to working with the company's management team and fellow board members to provide support in platform capability building, industrial cooperation expansion, and standardized operations, jointly supporting the company's steady development.”
About GeneRulor
GeneRulor is an innovative biotechnology enterprise specializing in gene editing technical services and safety assessment. The company has built a one-stop technology service platform covering early-stage research, preclinical studies, and IND submission support, focusing on areas such as gene editing tool development, off-target detection, vector integration risk assessment, gene editing efficacy validation, and CGT preclinical safety evaluation. In the future, GeneRulor will continue to adhere to independent technological innovation as its core, continuously improve the gene editing safety evaluation system, and assist global biopharmaceutical companies in accelerating the research, development, and clinical translation of innovative therapies.
